Hybrid Lipid/Polymer Nanoparticles to Tackle the Cystic Fibrosis Mucus Barrier in siRNA Delivery to the Lungs: Does PEGylation Make the Difference?-Reference-Cited by-同舟云学术

Hybrid Lipid/Polymer Nanoparticles to Tackle the Cystic Fibrosis Mucus Barrier in siRNA Delivery to the Lungs: Does PEGylation Make the Difference?

Published:2022-02-02 Issue:6 Volume:14 Page:7565-7578
ISSN:1944-8244
Container-title:ACS Applied Materials & Interfaces
language:en
Short-container-title:ACS Appl. Mater. Interfaces

Author:

Conte Gemma¹,Costabile Gabriella²,Baldassi Domizia³,Rondelli Valeria⁴^ORCID,Bassi Rosaria⁴,Colombo Diego⁴,Linardos Giulia⁵,Fiscarelli Ersilia V.⁵,Sorrentino Raffaella⁶,Miro Agnese²,Quaglia Fabiana²^ORCID,Brocca Paola⁴^ORCID,d’Angelo Ivana¹,Merkel Olivia M.³^ORCID,Ungaro Francesca²^ORCID

Affiliation:

1. Di.S.T.A.Bi.F., University of Campania Luigi Vanvitelli, Caserta 81100, Italy

2. Department of Pharmacy, University of Napoli Federico II, Napoli 80131, Italy

3. Department of Pharmacy, Pharmaceutical Technology and Biopharmacy, Ludwig-Maximilians-Universität, München, Munich 81377, Germany

4. Department of Medical Biotechnologies and Translational Medicine, University of Milano, Segrate (MI) 20090, Italy

5. Children’s Hospital Bambino Gesù IRCCS, Rome 00165, Italy

6. Department of Molecular Medicine and Medical Biotechnologies, University of Napoli Federico II, Napoli 80131, Italy

Funder

Ministero dell???Istruzione, dell???Universit?? e della Ricerca

Fondazione per la Ricerca sulla Fibrosi Cistica

Department of Medical Biotechnology and Translational Medicine, University of Milano

Publisher

American Chemical Society (ACS)

Subject

General Materials Science

Link

https://pubs.acs.org/doi/pdf/10.1021/acsami.1c14975

Reference58 articles.

1. Pulmonary delivery of siRNA as a novel treatment for lung diseases

2. Treating Cystic Fibrosis with mRNA and CRISPR

3. The current state and future directions of RNAi-based therapeutics

4. Formulation of RNA interference-based drugs for pulmonary delivery: challenges and opportunities

5. Barriers to inhaled gene therapy of obstructive lung diseases: A review

Cited by 48 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Lipid-Based Nanocarriers for Targeted Gene Delivery in Lung Cancer Therapy: Exploring a Novel Therapeutic Paradigm;Current Gene Therapy;2025-04

2. Ligand-free biodegradable poly(beta-amino ester) nanoparticles for targeted systemic delivery of mRNA to the lungs;Biomaterials;2025-02

3. PEI‐Engineered Lipid@PLGA Hybrid Nanoparticles for Multimodal Delivery of Antigens and Immune Adjuvants to the Respiratory Mucosa;Advanced Healthcare Materials;2024-09-11

4. Polyester nanoparticles delivering chemotherapeutics: Learning from the past and looking to the future to enhance their clinical impact in tumor therapy;WIREs Nanomedicine and Nanobiotechnology;2024-09

5. Advances and prospects of RNA delivery nanoplatforms for cancer therapy;Acta Pharmaceutica Sinica B;2024-09